EZH2 Inhibition in ARPI-Resistant Metastatic Prostate Cancer: Mechanism, Evidence, and Clinical Application

Experts explain how EZH2 fuels AR-inhibitor resistance in metastatic prostate cancer and why epigenetic targeting may restore response in trials.

New findings show EZH2 inhibition may not reverse lineage plasticity, but can rewire AR signaling and expand neuroendocrine tumor diversity.

New studies reveal EZH2 inhibition may not reverse prostate cancer lineage plasticity, instead fueling neuroendocrine diversity and AR rewiring.

How EZH2 inhibitors plus enzalutamide may restore AR therapy response, curb neuroendocrine shift, and delay prostate cancer resistance.

Explore MEV-Pro trials testing enzalutamide plus mevro metastate in mCRPC, from post-abiraterone to ARPI-naïve patients, aiming to delay resistance.

Inside MEV‑Pro trials: who qualifies for enzalutamide plus mevro metastate, and how the strategy targets mCRPC earlier to delay resistance.